肿瘤患者血清可溶性尿激酶受体检测的临床意义

Clinical significance of serum soluble urokinase receptor assay in tumor patients

目的 了解实体肿瘤患者血清可溶性尿激酶受体 (suPAR)水平以及恶性肿瘤患者血清suPAR水平与肿瘤浸润转移和治疗的关系。方法 应用免疫放射测定法 (IRMA)检测 6 2例健康成人、30例良性肿瘤患者与 12 4例恶性肿瘤患者血清suPAR水平并进行比较。结果 健康成人、良性肿瘤和恶性肿瘤患者血清suPAR水平分别为 (2 71± 1 12 ) μg/L、(3 71± 1 6 9) μg/L和 (5 82±2 2 7) μg/L。良、恶性肿瘤患者血清suPAR水平较健康对照增高 (P <0 0 1和P <0 0 0 1) ,而恶性肿瘤患者又高于良性肿瘤患者 (P <0 0 0 1)。恶性肿瘤患者血清suPAR水平与肿瘤细胞的浸润转移以及手术治疗有关。结论 检测血清suPAR水平对肿瘤患者的病情监测和疗效判断有较高的临床价值 。

Objective To investigate the clinical significance of soluble urokinase receptor (suPAR) measurement in evaluating clinical status of patients with solid malignant tumor.Methods suPAR levels in serum of 62 normal adults,30 patients with benign tumors and 124 patients with malignant tumors were measured by immunoradiometric assay.The association of suPAR level with tumor invasion,metastasis and its alteration after treatment in patients with malignant tumors were also studied.Results The serum suPAR levels were (2 71±1 12)μg/L in normal adults,(3 71±1 69)μg/L in patients with benign tumors and (5 82±2 27)μg/L in patients with malignant tumors,respectively.The serum suPAR level of two types of tumor patients was increased in comparison with that of normal adults( P< 0 01 and P< 0 001).And its increasing extent in malignant tumors was much greater than that in benign tumors( P< 0 001).The serum suPAR level of patients with malignant tumors was correlated with tumor invasion,metastasis and surgical intervention.Conclusions Our findings suggest that the serum suPAR level was increased in tumor patients,and that it might be used as a new tumor marker in clinic.